Chris Hancock, founder of Creo Medical Group PLC (AIM:CREO), delivered an insightful presentation at the Proactive One2One Investor Conference, emphasising Creo's innovative approach to cancer treatment.
Creo, established in 2002, specialises in advanced energy technologies, deploying them effectively to treat various cancers. Hancock highlighted the company's progress in gastrointestinal and lung cancer treatments, underscoring their revolutionary devices designed for minimally invasive surgeries.
The company's partnership with leading robotic firms has been a game changer, integrating their energy technology into robotic systems, enhancing the precision and safety of surgical procedures. This integration significantly benefits patient outcomes and is more cost-effective for healthcare providers. Creo's devices, particularly adept at treating colon cancer, have reportedly saved the NHS up to £10,000 per procedure.
Hancock showcased the FDA and CE-approved Speedboat device, notable for its efficiency in resecting, dissecting, and coagulating tissue. This device, lauded as a major advancement, enables surgeons to perform complex surgeries previously deemed impossible. Additionally, Creo's Microblade Flex, a flexible lung ablation device, has shown promising outcomes in clinical trials.
Creo's focus on minimally invasive techniques, like laparoscopic surgery, and its significant contributions to endoscopy and robotic surgery, demonstrate its commitment to advancing medical technology. The company's extensive research and development have led to numerous patent filings, reflecting their innovative approach to medical device design.
Their products, including the Speedo 3.7 and a pancreatic needle device, have revolutionized the way surgeries are conducted, particularly in the gastrointestinal tract. The company's achievements have not only improved patient outcomes but also positioned them as a preferred supplier to the NHS. This status underscores the effectiveness and economic benefits of their technology.
